Package insert (1)

Novel Coronavirus (2019-nCoV) IgM/IgG Antibody
Combo Test Kit (Colloidal Gold)
22-202003/R1
en
303002
22-202003/R1
303002
For prescription use only.
For in vitro diagnostic use only.
For Emergency Use Authorization (EUA) only.
Instruction for Use
1. INTRODUCTION.....................................................................................................................................................2
1.1 INTENDED USE...................................................................................................................................................... 2
1.2 BACKGROUND....................................................................................................................................................... 2
2. ABOUT THE LYHER KIT.......................................................................................................................................3
2.1 TEST PRINCIPLE................................................................................................................................................... 3
2.2 ASSAY KIT COMPONENTS................................................................................................................................. 3
2.3 COMPONENTS REQUIRED BUT NOT INCLUDED WITH THE TEST KIT.................................................. 3
2.4 STORAGE INSTRUCTIONS................................................................................................................................. 3
2.5 SPECIMEN COLLECTION AND PREPARATION............................................................................................. 3
2.6 TEST PROCEDURE .............................................................................................................................................. 4
3. WARNINGS AND PRECAUTIONS .......................................................................................................................4
3.1 INTERPRETATION OF THE RESULT................................................................................................................ 6
3.2 QUALITY CONTROL PROCEDURE ................................................................................................................... 7
4. LIMITATIONS..........................................................................................................................................................7
5. CONDITIONS OF AUTHORIZATION FOR LABORATORIES...........................................................................8
6. PERFORMANCE CHARACTERISTICS...............................................................................................................9
6.1 CLINICAL PERFORMANCE ................................................................................................................................. 9
6.2 CROSS-REACTIVITY .......................................................................................................................................... 10
INVITRODIAGNOSTICMEDICAL DEVICE TECHNICAL ASSISTANCE...............................................................12
22-202003/R1

LYHER®
Novel Coronavirus (2019-nCov) IgM/IgG Antibody Combo Test Kit
1. INTRODUCTION
1.1 INTENDED USE
The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) is a lateral flow
immunoassay intended for the qualitative detection of and differentiation of IgG and IgM antibodies to SARS-CoV-2 in serum
and plasma (dipotassium-EDTA, lithium-heparin, or sodium-citrate). The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG
Antibody Combo Test Kit (Colloidal Gold) is intended for use as an aid in identifying individuals with an adaptive immune
response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist
following infection and if the presence of antibodies confers protective immunity. Testing is limited to laboratories certified
under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, that meet requirements to perform
moderate or high complexity tests.
Results are for the detection of SARS CoV-2 antibodies. IgG and IgM antibodies to SARS-CoV-2 are generally detectable in
blood several days after initial infection, although the duration of time antibodies are present post-infection is not well
characterized. Individuals may have detectable virus present for several weeks following seroconversion.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public
health authorities.
The sensitivity of LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) early after
infection in unknown. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, direct
testing for SARS-CoV-2 is necessary.
False positive results for LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) may
occur due to cross-reactivity from pre-existing antibodies or other possible causes. Due to the risk of false positive results,
confirmation of positive results should be considered using second, different as appropriate, IgG or IgM assay.
The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) is only for use under the
Food and Drug Administration’s Emergency Use Authorization.
1.2 BACKGROUND
The novel coronaviruses belong to the β genus. COVID-19 is an acute respiratory infectious disease. People are generally
susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic
infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period
is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny
nose, sore throat, myalgia and diarrhea are found in a few cases.
The LYHER® Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit is intended for qualitative detection of
antibodies as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2 indicating recent or prior
SARS-CoV-2 infection.
2

LYHER®
2. ABOUT THE LYHER KIT
2.1 TEST PRINCIPLE
The LYHER® Kit uses an immunochromatography based technique in which a colloidal gold-labeled antibody is used as a
tracer to detect antibodies. The test panel contains (1) one colloidal gold-labeled recombinant COVID-19 S1 spike protein
antigen and quality control antibody colloidal gold marker, (2) two detection lines: G and M, (3) one quality control line: C.
The test area of nitrocellulose membrane is coated with mouse anti-human-IgM monoclonal antibody, mouse
anti-human-IgG monoclonal antibody and goat anti-mouse antibody were immobilized at test M, G, and C, respectively.
When an appropriate amount of test sample is loaded to LYHER® Kit, it will move along the nitrocellulose membrane. If the
specimen contains specific IgM/IgG antibodies against COVID-19, they will be captured by the mouse anti-human IgM/IgG
monoclonal antibodies coated in the test area to form a visible strip. If neither antibody is present, a negative result is
displayed. The Control Line is used as a procedural control. The control line should always appear if the test procedure is
performed properly and the reagents are working as intended.
2.2 ASSAY KIT COMPONENTS
1. Test device: one plate per bag
a. Sealed in an aluminum foil bag.
b. Contains immobilized SARS-CoV-2 spike antigen protein and mouse IgG labeled with colloidal gold,
respectively.
c. Goat anti-mouse IgG antibodies as a control.
2. Specimen diluent buffer: 1 vial (4.5mL per vial for 40 tests)
a. Contains 1.0% NaCl, 0.1% Na2HPO4 and 0.5% Casein.
Note: DO NOT mix components from different kit lots.
2.3 COMPONENTS REQUIRED BUT NOT INCLUDED WITH THE TEST KIT
1. Timer
2. Transfer pipet and pipette tips
3. Venipuncture specimen collection container
2.4 STORAGE INSTRUCTIONS
• Store in a dry place at 2-30 ℃, protected from light.
• The kit shall should be used within 30 minutes after the aluminum foil bag is opened.
• Testing should not be performed when the ambient temperature is higher than 30 ℃ or the relative humidity is
higher than 70%.
• The date for the manufacturing and the expiration date are printed on the outside of the package.
2.5 SPECIMEN COLLECTION AND PREPARATION
Consider any materials of human origin as infectious and handle using standard biosafety procedures.
Plasma:
1. Collect blood specimen into a clean, unused tube.
2. Separate the plasma by centrifugation.
3. Carefully withdraw the plasma into a new pre-labeled tube.
Serum:
1. Collect blood specimen into a clean, unused tube.
2. Allow the blood to clot.
3

LYHER®
3. Separate the serum by centrifugation.
4. Carefully withdraw the serum into a new pre-labeled tube.
Optimal performance of the kit depends upon the use of fresh plasma, serum samples (clear, non-hemolyzed, non-lipemic,
non-icteric). The amount of specimen with a minimum volume of 50 μL is recommended in case repeat testing is required.
Specimens should be collected aseptically by venipuncture.
Test specimens as soon as possible after collection. If specimens are not tested immediately, store at 2-8°C for up to 2
days. Samples that will not be tested within the time frame outlined above should be stored at ≤ -20 °C [≤ -4 °F]. For frozen
samples, avoid more than 1 freeze-thaw cycle. Prior to testing, bring frozen specimens to room temperature slowly and mix
gently.
Specimens containing visible particulate matter should be clarified by centrifugation before testing.
Do not use samples demonstrating gross lipemia, gross hemolysis or turbidity in order to avoid interference on result
interpretation.
2.6 TEST PROCEDURE
1. For fresh samples, begin with Step 2. For frozen samples, bring the specimens and test components to room
temperature, and mix the specimen well once thawed.
2. When ready to test, open the pouch and remove the test device. Place the test device on a clean, flat, dry surface.
3. Label the device with specimen ID number.
4. Add specimens:
• Serum/Plasma: Take 10 μL of serum or plasma with a pipette into sample well (S), and then add
vertically 2 drops (about 100 μL) of specimen diluent.
5. Set timer for 10 minutes.
6. Read the results at 10 minutes but no longer than 15 minutes.
3. WARNINGS AND PRECAUTIONS
CAUTION: The samples of this assay contains human sourced and/or potentially infectious components. As no
known test method can offer complete assurance that products derived from human sources or inactivated microorganisms
will not transmit infection. These human specimens should be handled as if infectious using laboratory safety procedures,
such as those outlined in Biosafety in Microbiological and Biomedical Laboratories, OSHA Standards on Bloodborne
Pathogens, CLSI Document M29-A4, and other appropriate biosafety practices. Therefore all human sourced materials
should be considered infectious. These precautions include, but are not limited to, the following:
• Wear gloves when handling specimens or reagents.
• Do not pipette by mouth.
• Do not eat, drink, smoke, apply cosmetics, or handle contact lenses in areas where these materials are handled.
• Clean and disinfect spills of specimens by including the use of a tuberculocidal disinfectant such as 1.0% sodium
hypochlorite or other suitable disinfectants.
• Decontaminate and dispose of all potentially infectious materials in accordance with local, state, and federal
regulations.
The LYHER® Kit’s specimen diluent buffer contains the following components:
4

LYHER®
• Sodium Chloride (EC no. 231-598-3)
• Disodium hydrogen phosphate (EC no. 231-448-7)
• Casein (EC no. 232-555-1)
The following warnings apply:
Warning
H317 May cause an allergic skin reaction
H319 Causes serious eye irritation
H315 Causes skin irritation
H402 Harmful to aquatic life*
H412 Harmful to aquatic life with long lasting effects
P261 Avoid breathing mist/vapors/spray
P264 Wash hands thoroughly after handling
P280 Wear protective gloves/protective clothing/eye protection
P273 Avoid release to the environment
P302 + P352 IF ON SKIN: wash with plenty of water
P333 + P313 If skin irritation or rash occurs: get medical advice/attention
P362 + P364 Take off contaminated clothing and wash before reuses
P305 + P351 + P338 IF IN EYES: rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P337 + P313 If eye irritation persists: get medical advice/attention.
P501 Dispose of contents/container in accordance with local regulations.
** Not applicable where regulation EC 1272/2008 (CLP) has been implemented.
Important information regarding the safe handling, transport, and disposal of this product is contained in the Safety Data
Sheet. It is available from your local distributor.
1. As with any test procedure, good laboratory practice is essential to the proper performance of this test. The LYHER®
Kit should be performed by qualified and trained staff to avoid the risk of erroneous results.
2. For in vitro diagnostic use only. For prescription use only.
3. This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by
laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests.
4. This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other
viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying
the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under
Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
5. All patient samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in
Microbiological and Biomedical Laboratories and in the CLSI Document M29-A4.3 Only personnel proficient in
handling infectious materials and the use of the Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit
should perform this procedure.
6. Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the
procedures and guidelines may affect optimal test performance.
5

LYHER®
7. False positive results may occur if carryover of samples is not adequately controlled during sample handling and
processing.
8. The LYHER® Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit is only for use with serum, plasma that
have been handled and stored as described in the Section 2.4 and 2.5 of this package insert.
9. Inadequate or inappropriate specimen collection, storage, and transport are likely to yield false test results. Training in
specimen collection is highly recommended due to the importance of specimen quality.
10. During preparation of samples, compliance with good laboratory practices is essential to minimize the risk of
cross-contamination between sample.
11. Excessive or inadequate samples may yield false or invalid results.
12. Components contained in the LYHER® Kit are intended to be used together. Do not mix components from different kit
lots. For example, do not use the device from lot X with the specimen diluent buffer from lot Y.
13. Do not use kits or reagents after the expiration dates shown on the labels.
14. Work area must be considered potential sources of contamination. Change gloves after contact with potential
contaminants (specimens) before handling unopened reagents, or specimens.
15. The test kit is sealed in a protective foil pouch. Do not use if pouch is damaged or open. Remove test kit from pouch just
prior to use. Do not touch the reaction area of test kit.
16. Do not use damaged test kit. Do not reuse the test kit.
17. Decontaminate and dispose of all potentially biohazardous materials in accordance with local, state, and federal
regulations. All materials should be handled in a manner that minimizes the chance of potential contamination of the
work area.
18. Humidity and temperature can adversely affect results.
3.1 INTERPRETATION OF THE RESULT
• IgG POSITIVE: * Two lines appear. The result is positive for IgG antibodies to the SARS-CoV-2. One colored line
should be in the control line region (C), and a colored line appears in the IgG test line region.
• IgM POSITIVE: *Two lines appear. The result is positive for IgM antibodies to the SARS-CoV-2. One colored line
should be in the control line region (C), and a colored line appears in the IgM test line region.
• IgG and IgM POSITIVE: *Three lines appear. The result is positive for both IgM and IgG antibodies to the
SARS-CoV-2. One colored line should be in the control line region (C), and two-colored lines should appear in IgG test
line region and IgM test line region.
*NOTE: The intensity of the color in the test line regions will vary depending on the antibodies against the novel
coronavirus present in the specimen. Therefore, any shade of color in the test line region should be considered
positive.
• NEGATIVE: One colored line appears in the control region (C). No apparent colored line appears in the IgG or IgM test
6

LYHER®
region (T).
• INVALID: Control line fails to appear. Insufficient sample volume or incorrect procedural techniques are the most likely
reasons for control line failure. Review the procedure and repeat the test with a new test cassette. If the problem
persists, discontinue using the test kit immediately and contact your local distributor.
3.2 QUALITY CONTROL PROCEDURE
A built-in procedural control on the card ensures that the test has been performed correctly; this pink/red colored lines
should always appear above the printed C line on the card. If a line does not appear in the control region, discard the card
as this is an invalid test and perform the test again.
CFUS Series 1000 and LHZG Series 2000 have been validated for use with this test kit. External positive and negative
controls should be tested consistent with good laboratory practice to confirm the test procedure and to verify proper test
performance. Both CFUS Series 1000 and LHZG Series 2000 can be procured by contacting your local distributors or
LYHER directly. Additional controls may be required according to guidelines or local, state, and/or federal regulations (such
as 42 CFR 493.1256) or accrediting organizations.
4. LIMITATIONS
For use under an Emergency Use Authorization only.
1. Use of LYHER® Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit is limited to laboratory
personnel who have been trained. Not for home use.
2. The test is limited to the qualitative detection of antibodies specific for the SARS-CoV-2 virus. The intensity of the
test line does not necessarily correlate to SARS-CoV-2 antibody titer in the specimen.
3. Performance has only been established with the specimen types listed in the Intended Use. This product is only
used for testing of individual serum, plasma samples. Other specimen types have not been evaluated and should
not be used with this assay.
4. The impacts of vaccines, antiviral therapeutics, antibiotics, chemotherapeutic or immunosuppressant drugs have
not been evaluated.
5. Results should be interpreted by a trained professional in conjunction with the patient’s history and clinical signs
and symptoms, and epidemiological risk factors.
6. It is not known at this time if the presence of antibodies to SARS-CoV-2 confers immunity to re-infection.
7. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient
management decisions. IgM antibodies may not be detected in the first few days of infection; the sensitivity of the
qSARS-CoV-2 IgG/IgM Rapid Test early after infection is unknown. False positive results for IgM and IgG
antibodies may occur due to cross-reactivity from pre-existing antibodies or other possible causes. Samples with
positive results should be confirmed with alternative testing method(s) and clinical findings.
8. A positive result may not indicate previous SARS-CoV-2 infection. Consider other information, including clinical
history and local disease prevalence, in assessing the need for a second but different serology test to confirm an
immune response.
9. False positive results may be produced if the amount of the added specimens exceeds the amount specified in this
instruction.
10. False negative results may arise from degradation of the antibodies during shipping/storage.
11. Serological antibody testing is of limited reference value in patients with impaired immune function or receiving
immunosuppressive therapy.
7

LYHER®
12. The target detection object of this product is IgM/IgG antibodies to the SARS-CoV-2. The positive results do not
directly reflect the presence of SARS-CoV-2 in the specimen of the patient.
13. The kit shall should be used within 30 minutes after the aluminum foil bag is opened.
14. Testing should not be performed when the ambient temperature is higher than 30 ℃ or the relative humidity is
higher than 70%.
15. The test should not be used for screening of donated blood.
5. CONDITIONS OF AUTHORIZATION FOR LABORATORIES
The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) Letter of Authorization,
along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Recipients, and authorized
labeling are available on the FDA website:
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/v
itro-diagnostics-euas
Authorized laboratories using the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal
Gold) (“your product” in the conditions below), must adhere to the Conditions of Authorization indicated in the Letter of
Authorization as listed below:
1. Authorized laboratories* using your product will include with test result reports, all authorized Fact Sheets. Under
exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may
include mass media.
2. Authorized laboratories using your product will use your product as outlined in the Instructions for Use. Deviations
from the authorized procedures, including the authorized clinical specimen types, authorized control materials,
authorized other ancillary reagents and authorized materials required to use your product are not permitted.
3. Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to
run your product prior to initiating testing.
4. Authorized laboratories using your product will have a process in place for reporting test results to healthcare
providers and relevant public health authorities, as appropriate.
5. Authorized laboratories will collect information on the performance of your product and report to
DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Hangzhou Laihe Biotech
(email: office@lyher.com; toll-free number: 1-888-291-2286) any suspected occurrence of false positive or false
negative results and significant deviations from the established performance characteristics of your product of
which they become aware.
6. All laboratory personnel using your product must be appropriately trained in immunoassay techniques and use
appropriate laboratory and personal protective equipment when handling this kit and use your product in
accordance with the authorized labeling. All laboratory personnel using the assay must also be trained in and be
familiar with the interpretation of results of the product.
7. Hangzhou Laihe Biotech Co., Ltd., authorized distributors, and authorized laboratories using your product will
ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will
be made available to FDA for inspection upon request.
*The letter of authorization refers to, “Laboratories certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity
tests” as “authorized laboratories.”
8

LYHER®
6. PERFORMANCE CHARACTERISTICS
6.1 CLINICAL PERFORMANCE
A total of 527 prospective and retrospective samples were obtained for this study. The PCR positive samples were
collected at four medical centers. Prospective specimens include samples from patients who tested positive for
SARS-CoV-2 using nucleic acid tests, samples from patients who recovered from COVID-19, and samples from individuals
who had contact with COVID-19 patients but tested negative with a SARS-CoV-2 nucleic acid test. The SARS-CoV-2
negative specimens include specimens that tested negative by a local hospital, specimens from patients with other
respiratory infections, and random specimens collected prior to August 2019.
Among the 178 specimens that were PCR positive, 90 were from patients who were still in quarantine and 88 were from
recovered patients. Among the 349 negative specimens in this trial, 239 of them were from patients with coronavirus
infections not caused by SARS-CoV-2, and 110 of them were patients with other respiratory tract infections (all 110 cases
were retrospective frozen specimens collected before August 2019).
Positive Results by Days After Onset of Symptoms (n=178)
Days from
Symptoms
Onset to Blood
Collection
Number
of PCR
Positive
Sample
LYHER IgM/IgG Antibody Combo Test Result Positive Percent Agreement
IgM+ IgG+
Both
IgM/IgG+
Both
IgM/IgG-
IgM IgG
≤ 6 days 23 23 0 0 0 23/23=100% 0/23=0.00%
7 – 14 days 21 5 0 13 3 18/21=85.71% 16/21=76.19%
>14 Days 134 2 1 131 0 133/134=99.25% 132/134=98.50%
Negative Results (n=349)
Number of
PCR Negative
Sample
LYHER IgM/IgG Antibody Combo Test Result Negative Percent Agreement
IgM- IgG-
Both
IgM/IgG+
Both
IgM/IgG-
IgM IgG
349 347 347 0 347 347/349=99.43% 347/349=99.43%
Independent Clinical Agreement Validation
The LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold) was tested on 6/10/2020 at
the Frederick National Laboratory for Cancer Research (FNLCR) sponsored by the National Cancer Institute (NCI). The
test was validated against a panel of previously frozen samples consisting of 30 SARS-CoV-2 antibody-positive serum
samples and 80 antibody-negative serum and plasma samples. Each of the 30 antibody-positive samples were confirmed
with a nucleic acid amplification test (NAAT) and both IgM and IgG antibodies were confirmed to be present in all 30
samples. The presence of antibodies in the samples was confirmed by several orthogonal methods prior to testing with the
COVID-19 IgG/IgM Rapid Test Cassette (Serum/Plasma). The presence of IgM and IgG antibodies specifically was
confirmed by one or more comparator methods. Antibody-positive samples were selected at different antibody titers.
All antibody-negative samples were collected prior to 2020 and include: i) Seventy (70) samples selected without regard to
clinical status, “Negatives” and ii) Ten (10) samples selected from banked serum from HIV+ patients, “HIV+”. Testing was
9

LYHER®
performed by one operator using one lot of the COVID-19 IgG/IgM Rapid Test Cassette (Serum/Plasma). Confidence
intervals for sensitivity and specificity were calculated per a score method described in CLSI EP12-A2 (2008).
For evaluation of cross-reactivity with HIV+, it was evaluated whether an increased false positive rate among
antibody-negative samples with HIV was statistically higher than the false positive rate among antibody-negative samples
without HIV (for this, a confidence interval for the difference in false positive rates was calculated per a score method
described by Altman). The results and data analysis are shown in the tables below.
Summary Results
COVID-19 IgG/IgM Rapid Test
Cassette (Serum/Plasma)
Comparator Method
Positive
(IgM/IgG) +
Negative
(IgM/IgG)-
Negative, HIV+ Total
Positive
IgM +/ IgG+ 29 0 0 29
IgM+, IgG- 0 0 0 0
IgM-, IgG+ 1 1 0 2
Negative IgM- / IgG)- 0 69 10 79
Total (n=110) 30 70 10 110
Summary Statistics
Measure Estimate Confidence Interval
IgM Sensitivity 96.7% (29/30) (83.3%; 99.4%)
IgG Sensitivity 100% (30/30) (95.4%; 100%)
(IgM+ or IgG+; Total) Sensitivity (PPA) 100% (30/30) (88.7%; 100%)
(IgM-/IgG-; Total) Specificity (NPA) 98.8% (79/80) (93.3%; 99.8%)
Cross-reactivity with HIV+
0% (0/10)
not detected
6.2 CROSS-REACTIVITY
Cross-reactivity of the LYHER® Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit was evaluated in two
studies using a total of 137 serum or plasma samples which contain antibodies to the pathogens listed below. All 137
specimens were negative by the LYHER® Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit. The data are
summarized in the following table:
No. Type of Specimens
Number of
LYHER IgM/IgG Antibody Combo
Test ResultSamples
Total IgM Neg Total IgG Neg
H1N1-1~H1N1-3
Anti-H1N1 IgM and IgG
Positive
3 3 3
H3N2-1
Positive
1 1 1
H5N1-1~H5N1-2
Positive
2 2 2
H7N9-1~H7N9-2
Positive
2 2 2
Yamagata-1 Anti-Yamagata IgM and IgG 1 1 1
10

LYHER®
Positive
Victoria-1~Victoria-4
Anti-Victoria IgM and IgG
Positive
4 4 4
RSV-1~RSV-2
Anti-RSV IgM and IgG
Positive
2 2 2
RUB-1~RUB-4
Anti-RUB IgM and IgG
Positive
4 4 4
CMV-1~CMV-5
Anti-CMV IgM and IgG
Positive
5 5 5
VZV-1~VZV-3
Anti-VZV IgM and IgG
Positive
3 3 3
HSV-1~HSV-6
Anti-HSV IgM and IgG
Positive
6 6 6
EBV-1~EBV-5
Anti-EBV IgM and IgG
Positive
5 5 5
Rotavirus-1~Rotavirus-
10
Rotavirus Antigen Test
Positive
10 10 10
Adenovirus-1~Adenovi
rus-2
Anti-Adenovirus IgM and IgG
Positive
2 2 2
Measles-1
Anti-Measles IgM and IgG
Positive
1 1 1
Enterovirus-1~Enterovi
rus-3
Anti-Enterovirus IgM and IgG
Positive
3 3 3
Mumps-1~Mumps-3
Anti-Mumps IgM and IgG
Positive
3 3 3
HIV-1
Anti-HIV IgM and IgG
Positive
1 1 1
Bacterium.P-1~Bacteri
um.P-2
Bacteriologic Test Positive 2 2 2
Chlamydia-1~Chlamyd
ia-3
Anti-Chlamydia IgM and IgG
Positive
3 3 3
M.P-1
Anti-Mycoplasma
Pneumoniae IgM and IgG
Positive
1 1 1
Legionella-1~Legionell
a-2
Anti-Legionella IgM and IgG
Positive
2 2 2
Strep.P-1
Streptococcus Pneumoniae
Antigen Test Postive
1 1 1
Staphyl.-1~Staphyl.-2
Bacteria culture result
Positive
2 2 2
RF-1~RF-2 Anti-RF IgM and IgG Positive 2 2 2
ANA-1 ANA Positive 1 1 1
Sample Category
Number of
Samples
LYHER IgM/IgG Antibody Combo Test Result
IgM IgG
Pos Neg %CR Pos Neg %CR
Anti-influenza A IgG Positive 5 0 5 0% 0 5 0%
Anti-influenza A IgM Positive 5 0 5 0% 0 5 0%
Anti-influenza B IgG Positive 5 0 5 0% 0 5 0%
Anti-influenza B IgM Positive 5 0 5 0% 0 5 0%
Anti-HCV IgG Positive 5 0 5 0% 0 5 0%
Anti-HCV IgM Positive 5 0 5 0% 0 5 0%
Anti-HBV IgG Positive 5 0 5 0% 0 5 0%
Anti-HBV IgM Positive 5 0 5 0% 0 5 0%
ANA Positive 5 0 5 0% 0 5 0%
Anti-respiratory syncytial virus IgG Positive 5 0 5 0% 0 5 0%
11

LYHER®
Anti-respiratory syncytial virus IgM Positive 5 0 5 0% 0 5 0%
Anti- Haemophilus influenzae IgG Positive 5 0 5 0% 0 5 0%
Anti- Haemophilus influenzae IgM Positive 5 0 5 0% 0 5 0%
Key to Symbols Used
For Prescription Use Only Caution
Warning
Manufacturer Date when the medical device was
manufactured
Consult Instructions For Use
In Vitro Diagnostic Medical Device Lot number
Use by
Temperature Limitation(2-30℃) Catalogue Number
Corrosive
Do not reuse Do not use if package is damaged Keep dry
INVITRODIAGNOSTICMEDICAL DEVICE TECHNICAL ASSISTANCE
Hangzhou Laihe Biotech Co., Ltd. © 2020 Laihe. All Rights
1st
Floor, Room 505 - 512, 5th
Floor, No.2B Building,
No.688, Bin’an Road, Changhe Jedao, Binjiang March 2020 22-202003/R1
District, Hangzhou, Zhejiang, People’s Republic of
China.
12

CFUSAnti-SARS-CoV-2ReferenceMaterialKit
Series 1000
CFUS Series 1000
About thispackageinsert
Thank you for your interest in this LYHER®product. This
package insert consists of two pages.
The first page contains the product name, the LYHER
logo, and contact information.
Thesecondpage contains thecompletepackageinsert text.
Ifthepackage insertyou vieworprint does not contain two
pages, or if you experience any problems, pleaseemailus .
A printed package insert will be sent to you upon request.
Key to Symbols Used
For Prescription In Vitro Diagnostic Date when the medical
Warning Manufacturer
Use Only Medical Device device was manufactured
Consult Temperature Limitation
Lot number Use by Instructions For Keep dry
( 2 to 8℃)
Use
Hangzhou Laihe Biotech Co.,Ltd.
Address:1st Floor,Room 505-5125thFloor,No.2BBuilding, No.688 Bin’an
Road, Changhe Jiedao,Binjiang District, Hangzhou, ZheJiang, PRC.

CFUSAnti-SARS-CoV-2ReferenceMaterialKitSeries1000
For use under an Emergency Use Authorization (EUA) only For
in vitro diagnostic use only. Rx only
NAME AND INTENDED USE
This product, CFUS Anti-SARS-CoV-2 Reference Material Kit Series 1000, is
formulated for use with the LYHER Novel Coronavirus (2019-nCoV) IgM/IgG
Antibody Combo Test Kit under the Emergency Use Authorization only.
PRODUCT DESCRIPTION
CFUSSeries1000includesbothantibodypositiveandnegativereference
materials. Thepositive is manufactured from human serum or plasma reactive for
SARS-CoV-2IgG/IgMandnonreactiveforHBsAgandantibodiestoHIV1and2,
HTLV Iand II,andHCV. There isasingle vialofpositivereference material (red
cap) contained within eachkit.
Thenegativereferencematerialismanufacturedfromhumanserumorplasma
nonreactive forantibodies toSARS-CoV-2, as wellas HBsAgand antibodies to
HIV1 and 2,HTLV Iand II,andHCV. There is a single vialofnegative reference
material (clear caps) contained within each kit.
PACKAGE DETAIL:
Positive (Red caps): 1x1.0mLvials
Negative(Clear caps): 1 x 1.0 mLvials
This control contains stabilizers (EDTA, buffering agents), and 0.1% ProClin®
(5- chloro-2-methyl- 4-isothiazolin-3-one & 2-methyl-4-isothiazolin-3-one) as
preservative.
WARNINGS AND PRECAUTIONS
CAUTION:HandleCFUSSeries1000andallhumanblood products
asthough capable of transmitting infectiousagents.
-This product has not been FDA cleared or approved;
-Thisproducthasbeenauthorized byFDA underanEUAforusebylaboratories
certifiedunderCLIA,thatmeetrequirementstoperformmoderateorhigh
complexity tests;
-This product is only authorized for the duration of the declaration that
circumstancesexistjustifyingtheauthorizationofemergencyuseofinvitro
diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
theFederalFood,DrugandCosmeticAct,21U.S.C.§360bbb-3(b)(1),unlessthe
authorization is terminated or revokedsooner.
Safety Precautions
Usethe Centers for Disease Control (CDC)recommended universal precautions for
handlingthisproductandhumanblood1.Donotpipettebymouth;donoteator
drink in areas where specimens are being handled. Clean any spillage by
immediatelywipingupwith0.5%sodiumhypochloritesolution.Disposeofall
specimens,referencematerials,andothermaterialsusedintestingasthoughthey
contain infectious agents.
Handling Precautions
Donot use CFUS Series1000 beyond theexpiration date. Avoid microbial
contamination of the reference materials when opening and closing thevials.
INDICATIONS OF REAGENT INSTABILITY OR DETERIORATION
Alterations in physical appearance may indicate instability or deterioration of CFUS
Series 1000. Solutions that are visibly turbid should be discarded.
STORAGE INSTRUCTIONS
Store CFUS Series 1000 at 2-8°C. Do not use beyond expiration
date. Once opened,vialsshould bestoredat2-8°C anddiscardedafter30days
orbythe expirationdate,whichevercomesfirst.Afteropening, recordthedate
opened andthe expiration date on thevial. Multiplefreeze-thaw cycles are not
recommended and mayhave variable adverseeffectsontestresults. To prevent
leakage,store vials upright.
INSTRUCTIONS FOR USE
Allow thereference materials to reach room temperature prior to use,then return
controls torefrigerated storage immediately after use. Mix thecontents of the vials by
gentlyswirling.FollowthestepswritteninthepackageinsertofLYHERNovel
Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit (Colloidal Gold). Use the
external control reference daily when there is testing performed.
INTERPRETATION OF RESULTS
Positiveexternalcontrolreferenceshouldgive positiveresultsforbothIgMandIgG;
negativeexternalcontrolreferenceshould give negativeresults.Iftheresultisnotas
expected,donotproceedthetestingandcontactLYHER immediately.
LIMITATIONS OF THE PROCEDURE
Testproceduresandinterpretation ofresultsprovided by LYHERmustbefollowed
closely. Any deviation from the procedure indicated in the package insert may produce
unreliable results.CFUSSeries1000isnot a calibrator and should not beused for
assaycalibration.Thisexternalcontrolreferencekitisforexclusiveusewiththe
LYHERNovelCoronavirus(2019-nCoV)IgM/IgGAntibodyComboTestKit
(Colloidal Gold).
Adverseshippingandstorageconditionsoruseofoutdatedproductmayproduce
erroneous results.
EXPECTED RESULTS
Specific levels of reactivity will vary among different procedures, different lot numbers
and different laboratories. Procedures for implementing a quality assurance program
and monitoring test performance on a routine basis must be established by each
authorized laboratory. Authorized laboratories should follow the range of acceptable
values established by LYHER.
REFERENCES
1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection
ControlPracticesAdvisoryCommittee,2007Guideline forIsolationPrecautions:
PreventingTransmissionofInfectious Agentsin Healthcare Settings.
For assistance, contact LYHER Technical Support at +1 888.291.2286
Address:1st Floor,Room 505-512 5thFloor, No.2B Building, No.688 Bin’an
Road, Changhe Jiedao ,Binjiang District, Hangzhou, ZheJiang, PRC.
20200720US-01 July 2020
LYHER.com

LHZGSeries2000-
Anti-SARS-CoV-2
Reference Material Kit
For in vitro diagnostic use only. Rx only.
For Emergency Use Authorization (EUA) only.
INTENDED USE
This product, LHZG Anti-SARS-CoV-2 Reference Material Kit Series
2000, is formulated for use with the LYHER Novel Coronavirus
(2019-nCoV) IgM/IgG Antibody Combo Test Kit under the
Emergency Use Authorization only.
LHZG Series 1200 includes includes both antibody positive and
negative reference materials. The positive is manufactured from
humanized anti-SARS-CoV-2 IgG/IgM monoclonal antibodies in
newborn calf serum buffer.
The negative reference material is manufactured from newborn
calf serum buffer with no reactive antibodies to SARS-CoV-2.
All test results should be within the required reference range
PACKAGE SPECIFICATION
Each box includes a total number of 10 tubes (5 positive and 5
negative)
 Positive: 200uL x 5 vials
 Negative: 200uL x 5 vials
STORAGE INSTRUCTIONS
LHZG Series 2000 can be stored at -20±5°C until
expiration date, and at 2-8°C for 1 month. DO NOT
use beyond expiration date. Once opened, vials should be stored at
2-8°C and discarded after 30 days or by the expiration date,
whichever comes first. After opening, record the date opened and
the expiration date on the vial. Multiple freeze-thaw cycles are not
recommended and may have variable adverse effects on test
results. To prevent leakage, store vials upright.
WARNINGS AND PRECAUTIONS
For in vitro diagnostic use only. For Emergency Use
Authorization (EUA) only.
 This product has not been FDA cleared or approved; this product
has been authorized by FDA under an EUA for use by
laboratories certified under CLIA, that meet requirements to
perform moderate or high complexity tests.
 This product is only authorized for the duration of the declaration
that circumstances exist justifying the authorization of emergency
use of in vitro diagnostics for detection and/or diagnosis of
COVID-19 under Section 564(b)(1) of the Federal Food, Drug
and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
authorization is terminated or revoked sooner.
 As with any test procedure, good laboratory practice is essential
to the proper performance of this test. The test should be
performed by qualified and trained staff to avoid the risk of
erroneous results.
 Work area must be considered potential sources of
contamination. Change gloves after contact with potential
contaminants (specimens) before handling unopened reagents,
or specimens.
 Once the product is opened, please store it under the condition of
2-8℃. The shelf life is one month.
Handling Precautions
Do not use LYHER reference materials beyond the expiration date.
Avoid microbial contamination of the reference materials when opening
and closing the vials.
INDICATIONS OF REAGENT
INSTABILITY OR DETERIORATION
Alterations in physical appearance may indicate instability or
deterioration of LHZG Series 2000. Solutions that are visibly turbid
should be discarded.
INSTRUCTION FOR USE
Allow the reference materials to reach room temperature prior to use.
1. Pipette 10 μL of positive control or negative control into sample
well (S) with the pipette.
2. Add vertically 2 drops (about 100μL) of specimen diluent.
3. Record results at 10 minutes.
4. Return controls to refrigerated storage immediately after use.
Use the external control reference daily when there is testing
performed.
INTERPRETATION OF RESULTS
Positive external control reference should give positive results for both
IgM and IgG; negative external control reference should give negative
results. If the result is not as expected, do not proceed the testing and
contact LYHER immediately.
SAFETY PRECAUTIONS
Use the Centers for Disease Control (CDC) recommended universal
precautions for handling this product and human blood1. Do not
pipette by mouth; do not eat or drink in areas where specimens are
being handled. Clean any spillage by immediately wiping up with 0.5%
sodium hypochlorite solution. Dispose of all specimens, reference
materials, and other materials used in testing as though they contain
infectious agents.
LIMITATION OF THE PROCEDURE
Test procedures and interpretation of results provided by LYHER
must be followed closely. Any deviation from the procedure indicated
in the package insert may produce unreliable results. LHZG Series
2000 is not a calibrator and should not be used for assay calibration.
This external control reference kit is for exclusive use with the LYHER
Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit
(Colloidal Gold). Adverse shipping and storage conditions or use of
outdated product may produce erroneous results.
EXPECTED RESULTS
Specific levels of reactivity will vary among different procedures,
different lot numbers and different laboratories. Procedures for
implementing a quality assurance program and monitoring test
performance on a routine basis must be established by each
authorized laboratory. Authorized laboratories should follow the
range of acceptable values established by LYHER.
REFERENCES
1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare
Infection Control Practices Advisory Committee, 2007 Guideline for
Isolation Precautions: Preventing Transmission of Infectious Agents
in Healthcare Settings.
For assistance, contact LYHER Technical Support

Key to Symbols Used
For Prescription In Vitro Diagnostic Date when the medical
Warning Manufacturer
Use Only Medical Device device was manufactured
Consult
Temperature Limitation
Lot number Use by Instructions For Keep dry
(-25 to -15℃)
Use
Address: 1st Floor, Room 505-512 5th Floor, No.2B Building, No.688 Bin’an Road,
Changhe Jiedao ,Binjiang District, Hangzhou, ZheJiang, PRC.

Package insert (1)

More Related Content

What's hot (20)

Similar to Package insert (1) (20)

More from HK HuZef (11)

Recently uploaded (20)

Package insert (1)